Last reviewed · How we verify

Maintenance icotinib — Competitive Intelligence Brief

Maintenance icotinib (Maintenance icotinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR tyrosine kinase inhibitor (TKI). Area: Oncology.

marketed EGFR tyrosine kinase inhibitor (TKI) EGFR (epidermal growth factor receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Maintenance icotinib (Maintenance icotinib) — Betta Pharmaceuticals Co., Ltd.. Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Maintenance icotinib TARGET Maintenance icotinib Betta Pharmaceuticals Co., Ltd. marketed EGFR tyrosine kinase inhibitor (TKI) EGFR (epidermal growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR tyrosine kinase inhibitor (TKI) class)

  1. Betta Pharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Maintenance icotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/maintenance-icotinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: